Hyperkalemia is a medical condition in which levels of potassium in the blood are abnormally high. It occurs when renal potassium excretion is impaired by reductions in glomerular filtration rate, tubular flow, distal sodium delivery, or by disturbance of the renin–angiotensin–aldosterone system (RAAS).
This potentially life-threatening electrolyte disorder occurs with greater frequency in patients with renal disease, heart failure, and in patients who use certain medications, such as renin–angiotensin–aldosterone system inhibitors (RAASis).
For chronic hyperkalemia, treatment goals include normalizing potassium levels and maintaining of normokalemia in order to prevent further hyperkalemia episodes, in addition to allowing patients to optimize RAASi therapy.
Hyperkalemia is defined as an abnormally high level of potassium in the serum. Potassium typically is categorized in three ranges – Normokalemia, Hypokalemia, and Hyperkalemia.
This informational video, led by Dr. Ileana Pina, focuses on defining hyperkalemia and why it occurs in patients with heart failure.
Hyperkalemia has been observed in landmark clinical trials employing Renin Angiotensin Aldosterone inhibitors (RAASi) and Mineralocorticoid Receptor Antagonists (MRAs). Data from the Swedish Heart Failure registry shows higher rates of hyperkalemia in routine clinical practice than what has generally been reported in the clinical trial setting.
This informational video, led by Mikhail Kosiborod, discusses the prevalence of hyperkalemia in patients with heart failure.
The balance between intracellular and extracellular potassium levels is critical for maintaining the electrical potential of most cells. Both hypo- and hyperkalemia are associated with increased mortality.
This informational video, led by Dr. Ileana Pina, focuses on the life-threatening consequences of hyperkalemia.
Renin Angiotensin Aldosterone System inhibition (RAASi) at submaximum doses or discontinuation of RAASi was associated with increased rates of mortality in patients with heart failure.
This informational video, led by Dr. Mikhail Kosiborod, addresses the considerations for patients with heart failure.
Renin Angiotensin Aldosterone System inhibitors are the cornerstone of therapy for patients with heart failure with reduced ejection fraction or HFrEF. Due to their benefits in reducing morbidity and mortality, these agents have been given a Class I recommendation in the ACC/AHA/HFSA Treatment Guidelines.
This informational video, led by Dr. Javed Butler, reviews the ACC/AHA/HFSA guidelines for RAASi in HFrEF.
This is me, continue